A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin [doxorubicin] in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2005
At a glance
- Drugs Keyhole limpet haemocyanin (Primary) ; Doxorubicin
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- 19 Sep 2005 New trial record.